EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Avalo Therapeutics's enterprise value is $10.54 Mil.
Avalo Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1.93 Mil. Therefore, Avalo Therapeutics's EV-to-Revenue for today is 5.47.
The historical rank and industry rank for Avalo Therapeutics's EV-to-Revenue or its related term are showing as below:
AVTX'
s EV-to-Revenue Range Over the Past 10 Years
Min: -1605.48 Med: 8.45 Max: 139.06
Current: 5.47
During the past 11 years, the highest EV-to-Revenue of Avalo Therapeutics was 139.06. The lowest was -1605.48. And the median was 8.45.
AVTX's EV-to-Revenue is ranked better than 61.03% of 1034
companies
in the Biotechnology industry
Industry Median: 7.775
vs AVTX: 5.47
The historical data trend for Avalo Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Avalo Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Avalo Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalo Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Avalo Therapeutics's EV-to-Revenue falls into.
Avalo Therapeutics's current Enterprise Value is $10.54 Mil.
Avalo Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalo Therapeutics's share price for today is $16.44.
Avalo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.70.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalo Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Avalo Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Avalo Therapeutics (Avalo Therapeutics) Business Description
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVTX has been successfully added to your 